Life Sciences Market Trends & Deal Drivers: Insights from McDermott & EY | McDermott

VIRTUAL

Key takeaways | Life Sciences Market Trends & Deal Drivers: Insights from McDermott & EY

July 22, 2026

Event details

July 22, 2026

12:00 pm (ET)

Webinar

This event is in the past. See recordings and other materials from this event below.

McDermott Will & Schulte and EY explored the forces shaping today’s global life sciences market in a timely discussion that built on insights from our annual McDermott Forum at JPM. The webinar took a deeper look at the trends actually moving the needle across biopharma, MedTech, and diagnostics as the industry reached the midpoint of 2026.

With the industry heading into a critical stretch leading up to major convenings – including McDermott’s Life Sciences Investment Forum and AdvaMed’s MedTech Conference – the discussion cut through the noise to focus on what matters most for investors, operators, and innovators right now, including the growing impact of cross-border dynamics and China’s evolving role in the global life sciences ecosystem.

Key takeaways included:

  1. Life sciences dealmaking is accelerating, but buyers are becoming more selective. 2026 is shaping up to be a breakout year for life sciences transactions, with larger, more strategic deals driving activity. Buyers are prioritizing assets that strengthen pipelines, support long-term growth, and create lasting value.

  2. Companies are looking earlier in the pipeline for innovation. As patent expirations approach, biopharma companies are increasingly pursuing earlier-stage assets through licensing agreements, partnerships, and milestone-based deal structures that balance innovation with risk.

  3. MedTech investment is focused on technology-driven growth. Strategic buyers are targeting AI, diagnostics, connected care, and other high-growth technologies, while favoring flexible deal structures that accelerate innovation and platform expansion.

  4. Cross-border partnerships are reshaping the market. China continues to emerge as a key source of life sciences innovation, driving increased licensing and collaboration activity while also introducing new geopolitical and regulatory considerations for dealmakers.  

To view the webinar presentation materials, click here.

Webinar recording
Speakers